DrugPatentWatch Database Preview
Lifitegrast - Generic Drug Details
What are the generic drug sources for lifitegrast and what is the scope of patent protection?
Lifitegrast
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lifitegrast has one hundred and six patent family members in twenty-one countries.
One supplier is listed for this compound.
Summary for lifitegrast
| International Patents: | 106 |
| US Patents: | 15 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 24 |
| Clinical Trials: | 11 |
| Patent Applications: | 62 |
| DailyMed Link: | lifitegrast at DailyMed |
Recent Clinical Trials for lifitegrast
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Toyos Clinic | Phase 4 |
| Sun Pharmaceutical Industries Limited | Phase 4 |
| Shire Human Genetic Therapies, Inc. | Phase 4 |
Pharmacology for lifitegrast
| Drug Class | Lymphocyte Function-Associated Antigen-1 Antagonist |
| Mechanism of Action | Lymphocyte Function-Associated Antigen-1 Antagonists |
Synonyms for lifitegrast
| (2S)-2-(((2-(Benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
| (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid |
| (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid |
| 038E5L962W |
| 1025967-78-5 |
| 1356856-75-1 |
| 915397-62-5 |
| AKOS030628489 |
| BDBM50386331 |
| CHEBI:133023 |
| CHEMBL2048028 |
| compound 1g [PMID: 24900456] |
| CS-6264 |
| D10374 |
| DB11611 |
| DS-20052 |
| DTXSID60145345 |
| EX-A2582 |
| GTPL7533 |
| HY-19344 |
| L-Phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)- |
| Lifitegrast (USAN/INN) |
| Lifitegrast [USAN:INN] |
| Lifitegrast; SAR 1118 |
| MolPort-044-727-763 |
| N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-L-phenylalanine |
| SAR 1118 |
| SAR-1118 |
| SAR1118 |
| SB18920 |
| SCHEMBL2632068 |
| UNII-038E5L962W |
| Xiidra |
| Xiidra (TN) |
| ZINC84668739 |
US Patents and Regulatory Information for lifitegrast
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novartis | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Novartis | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Novartis | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Novartis | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for lifitegrast
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2265125 | Start Trial |
| Canada | 2702984 | Start Trial |
| Australia | 2019210525 | Start Trial |
| Japan | 2017141310 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009128934 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
